Skip to main content
. 2020 Aug 25;78(6):ftaa042. doi: 10.1093/femspd/ftaa042

Figure 5.

Figure 5.

Diagrammatic representation of SARS-CoV-2 targets, for the neutralizing antibodies, vaccines design and various entry/fusion inhibitors.